Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 9월 2023 - 9:30PM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the
“Company”), a specialty pharmaceutical company focused on the
development and commercialization of therapies for the treatment of
neurologic diseases, today announced that Alexandra MacLean, M.D.,
Chief Executive Officer, will present a corporate update at the
H.C. Wainwright 25th Annual Global Investment Conference scheduled
to take place September 11-13, 2023. The presentation will be
available for on-demand viewing starting Monday, September 11, 2023
at 7:00 a.m. ET.
A webcast and subsequent archived replay of the
company presentation will be available on the Events page of
Avenue’s website: https://avenuetx.com/ for approximately 30 days
following the meeting.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a
specialty pharmaceutical company focused on the development and
commercialization of therapies for the treatment of neurologic
diseases. It is currently developing three assets including AJ201,
a first-in-class oral small molecule for spinal and bulbar muscular
atrophy, BAER-101, an oral small molecule selective GABA-A α2/3
receptor positive allosteric modulator for CNS diseases, and IV
tramadol, which is in Phase 3 clinical development for the
management of moderate-to-moderately-severe pain in adults in a
medically supervised healthcare setting. Avenue is headquartered in
Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).
For more information, visit www.avenuetx.com.
Contact: Jaclyn Jaffe Avenue Therapeutics, Inc.
(781) 652-4500ir@avenuetx.com
Avenue Therapeutics (NASDAQ:ATXI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Avenue Therapeutics (NASDAQ:ATXI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
